2022 World Conference on Lung Cancer (ePosters)-EP08.02-154. Aumolertinib Plus Anlotinib as 1st-Line Treatment for EGFR Mutant Non-Small Cell Lung Cancer: A Phase II Trial

EP08.02-154. Aumolertinib Plus Anlotinib as 1st-Line Treatment for EGFR Mutant Non-Small Cell Lung Cancer: A Phase II Trial

Back to course

Pdf Summary

A phase II clinical trial investigated the use of the combination of Aumolertinib and Anlotinib as a first-line treatment for EGFR mutant non-small cell lung cancer (NSCLC). The study aimed to explore new treatment options and prolong progression-free survival in these patients.<br /><br />The trial included patients with advanced EGFR mutant NSCLC who had not received prior systemic treatment. They were treated with Aumolertinib orally once daily and Anlotinib orally once daily for a 3-week cycle program. The primary endpoint of the study was progression-free survival, and secondary endpoints included objective response rate, disease control rate, overall survival, duration of response, and safety.<br /><br />The study found that the combination therapy of Aumolertinib and Anlotinib showed preliminary efficacy and a tolerable safety profile in EGFR-mutated NSCLC patients. The objective response rate was 100%, with 71.4% of patients achieving an objective response in the central nervous system. Importantly, the observed objective response rate was better than reported first-line response rates for EGFR-mutated NSCLC with other EGFR-TKIs.<br /><br />The combination therapy also demonstrated preliminary efficacy in patients with brain metastases. None of the patients discontinued the treatment due to adverse reactions. The study is still ongoing, and the long-term outcomes will be further observed.<br /><br />In conclusion, the combination of Aumolertinib and Anlotinib as a first-line treatment for EGFR mutant NSCLC shows promising results in terms of efficacy and safety. This study provides new insights into potential treatment options for these patients and offers a potential strategy for prolonging progression-free survival.

Asset Subtitle

Hualin Chen

Meta Tag

Speaker Hualin Chen

Topic Metastatic Non-small Cell Lung Cancer - Molecular Targeted Treatments

Keywords

phase II clinical trial

Aumolertinib

Anlotinib

first-line treatment

EGFR mutant non-small cell lung cancer

NSCLC

progression-free survival

advanced EGFR mutant NSCLC

combination therapy

objective response rate